An LXRβ agonist, or a pharmaceutically acceptable salt thereof, for use in treating metastatic cancer in a subject in need thereof by increasing the expression level or the activity level of ApoE, where the metastatic cancer is resistant to an antiproliferative from Table 2 and the LXRβ agonist is: ** (See formula) ** or a pharmaceutically acceptable salt thereof.